ArticleBriefings in bioinformatics2024
Attribute-guided prototype network for few-shot molecular property prediction.
Article in Briefings in bioinformatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- HD-SKRG: a hierarchical dual-view and structure-knowledge relation graph enhancement network for few-shot molecular property prediction.Molecular diversity · 2026Article
- Organic Chemistry as a Catalyst for AI Innovation: Challenges, Methods, and Emerging Paradigms.Chemical reviews · 2026Review
- Small data, big challenges: Machine- and deep-learning strategies for data-limited drug discovery.Advanced drug delivery reviews · 2026Review
- ProtoMol: enhancing molecular property prediction via prototype-guided multimodal learning.Briefings in bioinformatics · 2025Article
- An image-based protein-ligand binding representation learning framework via multi-level flexible dynamics trajectory pre-training.Bioinformatics (Oxford, England) · 2025Article
- MaskMol: knowledge-guided molecular image pre-training framework for activity cliffs with pixel masking.BMC biology · 2025Article
- Context-informed few-shot molecular property prediction via heterogeneous meta-learning.Computational and structural biotechnology journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The molecular property prediction (MPP) plays a crucial role in the drug discovery process, providing valuable insights for molecule evaluation and screening. Although deep learning has achieved numerous advances in this area, its success often depends on the availability of substantial labeled data. The few-shot MPP is a more challenging scenario, which aims to identify unseen property with only few available molecules. In this paper, we propose an attribute-guided prototype network (APN) to address the challenge. APN first introduces an molecular attribute extractor, which can not only extract three different types of fingerprint attributes (single fingerprint attributes, dual fingerprint attributes, triplet fingerprint attributes) by considering seven circular-based, five path-based, and two substructure-based fingerprints, but also automatically extract deep attributes from self-supervised learning methods. Furthermore, APN designs the Attribute-Guided Dual-channel Attention module to learn the relationship between the molecular graphs and attributes and refine the local and global representation of the molecules. Compared with existing works, APN leverages high-level human-defined attributes and helps the model to explicitly generalize knowledge in molecular graphs. Experiments on benchmark datasets show that APN can achieve state-of-the-art performance in most cases and demonstrate that the attributes are effective for improving few-shot MPP performance. In addition, the strong generalization ability of APN is verified by conducting experiments on data from different domains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.